Sleep Disorders in Multiple Sclerosis

W. Elon Fleming; Charles P. Pollak

doi:10.1055/s-2005-867075

Seminars in Neurology, Table of Contents

Semin Neurol 2005; 25(1): 64-68
DOI: 10.1055/s-2005-867075

Sleep Disorders in Multiple Sclerosis

W. Elon Fleming¹ , Charles P. Pollak²

¹Sleep Disorders Center, Island Hospital, Anacortes, Washington
²Sleep Laboratory, Cornell Medical Center, New York, New York

Abstract

ABSTRACT

Sleep disorders are pervasive in patients with multiple sclerosis (MS) although clinically underrecognized by most physicians. The most common sleep disorders seen in patients with MS include insomnia, nocturnal movement disorders, sleep-disordered breathing, narcolepsy, and rapid eye movement sleep behavior disorder. Factors that influence the quality of sleep in this patient population include pain, nocturia, depression, medication effect, location of lesions, and disease severity. Disrupted sleep has the potential to cause daytime somnolence, increased fatigue, and nonrefreshing sleep, and it may be associated with dangerous respiratory events. Awareness and treatment of these conditions is vital to improving health and quality of life in patients with MS.

KEYWORDS

Sleep disorders - multiple sclerosis - insomnia - narcolepsy

Full Text

References

REFERENCES

1 Tachibana N, Howard R S, Hirsch N P, Miller D H, Moseley I F, Fish D. Sleep problems in multiple sclerosis. Eur Neurol. 1994; 34 320-323
2 Saunders J, Whitham R, Schaumann B. Sleep disturbance, fatigue, and depression in multiple sclerosis. Neurology. 1991; 41(suppl 1) 320
3 Leo G J, Rao M, Bernardin L. Sleep disturbances in multiple sclerosis. Neurology. 1991; 41(suppl 1) 320
4 Achiron A, Barak Y, Gabbay U. Sleep disturbance in multiple sclerosis: clinical and neuroradiologic correlations related to disease activity. J Neuroimmunol. 1995; 56-63(suppl 1) 57
5 Ford D E, Kamerow D B. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention?. JAMA. 1989; 262 1479-1484
6 Sadovnick A D, Remick R A, Allen J et al.. Depression and multiple sclerosis. Neurology. 1996; 46 628-632
7 Feinstein A, Kartsounis L D, Miller D H, Youl B D, Ron M A. Clinically isolated lesions of the type seen in multiple sclerosis: a cognitive, psychiatric, and MRI follow up study. J Neurol Neurosurg Psychiatry. 1992; 55 869-876
8 Fruehwald S, Loeffler-Stastka H, Eher R, Saletu B, Baumhackl U. Depression and quality of life in multiple sclerosis. Acta Neurol Scand. 2001; 104 257-261
9 Rae-Grant A D, Eckert N J, Bartz S, Reed J F. Sensory symptoms of multiple sclerosis: a hidden reservoir of morbidity. Mult Scler. 1999; 5 179-183
10 Ferini-Strambi L, Filippi M, Martinelli V et al.. Nocturnal sleep study in multiple sclerosis: correlations with clinical and brain magnetic resonance imaging findings. J Neurol Sci. 1994; 125 194-197
11 Coleman R M, Pollak C P, Weitzman E D. Periodic movements in sleep (nocturnal myoclonus): relation to sleep disorders. Ann Neurol. 1980; 8 416-421
12 Ekbom K A. Restless legs: a clinical study. Acta Med Scand Suppl. 1945; 158 1
13 Strang R R. The symptom of restless legs. Med J Aust. 1967; 1 1211-1213
14 Lavigne G J, Montplaisir J Y. Restless legs syndrome and sleep bruxism: prevalence and association among Canadians. Sleep. 1994; 17 739-743
15 Coleman R M, Bliwise D L, Sajben N et al.. Epidemiology of periodic limb movements during sleep. In: Guilleinault C, Lugaresi E Sleep/Wake Disorders: Natural History, Epidemiology and Long Term Evolution New York; Raven Press 1988: 217-229
16 Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lesperance P. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord. 1997; 12 61-65
17 Montplaisir J, Lapierre O, Warnes H, Pelletier G. The treatment of the restless leg syndrome with or without periodic leg movements in sleep. Sleep. 1992; 15 391-395
18 Lugaresi E, Cirignotta F, Coccagna G, Montagna P. Nocturnal myoclonus and restless legs syndrome. Adv Neurol. 1986; 43 295-307
19 Desautels A, Turecki G, Montplaisir J, Sequeira A, Verner A, Rouleau G A. Identification of a major susceptibility locus for restless legs syndrome on chromosome 12q. Am J Hum Genet. 2001; 69 1266-1270
20 Bonati M T, Ferini-Strambi L, Aridon P, Oldani A, Zucconi M, Casari G. Autosomal dominant restless legs syndrome maps on chromosome 14q. Brain. 2003; 126 1485-1492
21 Onen S H, Alloui A, Gross A, Eschallier A, Dubray C. The effects of total sleep deprivation, selective sleep interruption and sleep recovery on pain tolerance thresholds in healthy subjects. J Sleep Res. 2001; 10 35-42
22 Solaro C, Uccelli M M, Guglieri P, Uccelli A, Mancardi G L. Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis. Mult Scler. 2000; 6 192-193
23 Amarenco G, Kerdraon J, Denys P. [Bladder and sphincter disorders in multiple sclerosis. Clinical, urodynamic and neurophysiological study of 225 cases]. Rev Neurol (Paris). 1995; 151 722-730
24 Leo G J, Rao S M, Bernardin L. Sleep disturbance in multiple sclerosis. Neurology. 1991; 41(suppl 1) 320 , (Abstract)
25 Nuotio M, Tammela T L, Luukkaala T, Jylha M. Predictors of institutionalization in an older population during a 13-year period: the effect of urge incontinence. J Gerontol A Biol Sci Med Sci. 2003; 58 756-762
26 Valiquette G, Herbert J, Maede-D'Alisera P. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Arch Neurol. 1996; 53 1270-1275
27 Rebif®. Product information, 2002
28 Huber S, Spycher M, Lechner-Scott J, Bellaiche Y, Steck A J, Kappos L. [Multiple sclerosis: therapy with recombinant beta-1b interferon: initial results with 30 multiple sclerosis patients in northwest Switzerland]. Schweiz Med Wochenschr. 1996; 126 1475-1481
29 Antonijevic I A, Steiger A. Depression-like changes of the sleep-EEG during high dose corticosteroid treatment in patients with multiple sclerosis. Psychoneuroendocrinology. 2003; 28 780-795
30 Patten S B, Fridhandler S, Beck C A, Metz L M. Depressive symptoms in a treated multiple sclerosis cohort. Mult Scler. 2003; 9 616-620
31 Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993; 328 1230-1235
32 Auer R N, Rowlands C G, Perry S F, Remmers J E. Multiple sclerosis with medullary plaques and fatal sleep apnea (Ondine's curse). Clin Neuropathol. 1996; 15 101-105
33 Wunderlin B W, Kesselring J, Ginzler H et al.. Fatigue in multiple sclerosis is not due to sleep apnea. Eur J Neurol. 1997; 4 72-78
34 Howard R S, Wiles C M, Hirsch N P, Loh L, Spencer G T, Newsom-Davis J. Respiratory involvement in multiple sclerosis. Brain. 1992; 115 479-494
35 Schrader H, Gotlibsen O B, Skomedal G N. Multiple sclerosis and narcolepsy/cataplexy in a monozygotic twin. Neurology. 1980; 30 105-108
36 Bonduelle M, Degos C. Symptomatic narcolepsies: a critical study. In: Guilleminault C, Dement WC, Passouant P Narcolepsy New York; Spectrum 1976: 322-325
37 Langdon N, Welsh K I, van Dam M, Vaughan R W, Parkes D. Genetic markers in narcolepsy. Lancet. 1984; 2 1178-1180
38 Caballero A, Alves-Leon S, Papais-Alvarenga R, Fernandez O, Navarro G, Alonso A. DQB1*0602 confers genetic susceptibility to multiple sclerosis in Afro-Brazilians. Tissue Antigens. 1999; 54 524-526
39 Mignot E, Lin X, Arrigoni J et al.. DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans. Sleep. 1994; 17(suppl 8) S60-S67
40 Juji T, Satake M, Honda Y, Doi Y. HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive. Tissue Antigens. 1984; 24 316-319
41 Duquette P, Decary F, Pleines J et al.. Clinical sub-groups of multiple sclerosis in relation to HLA: DR alleles as possible markers of disease progression. Can J Neurol Sci. 1985; 12 106-110
42 Younger D S, Pedley T A, Thorpy M J. Multiple sclerosis and narcolepsy: possible similar genetic susceptibility. Neurology. 1991; 41 447-448
43 Iseki K, Mezaki T, Oka Y et al.. Hypersomnia in MS. Neurology. 2002; 59 2006-2007
44 Billiard M, Besset A, Montplaisir J et al.. Modafinil: a double-blind multicentric study. Sleep. 1994; 17(suppl 8) S107-S112
45 Kato T, Kanbayashi T, Yamamoto K et al.. Hypersomnia and low CSF hypocretin-1 (orexin-A) concentration in a patient with multiple sclerosis showing bilateral hypothalamic lesions. Intern Med. 2003; 42 743-745
46 Rammohan K W, Rosenberg J H, Lynn D J, Blumenfeld A M, Pollak C P, Nagaraja H N. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry. 2002; 72 179-183
47 Scammell T E, Estabrooke I V, McCarthy M T et al.. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci. 2000; 20 8620-8628
48 Tison F, Wenning G K, Quinn N P, Smith S J. REM sleep behaviour disorder as the presenting symptom of multiple system atrophy. J Neurol Neurosurg Psychiatry. 1995; 58 379-380
49 Uchiyama M, Isse K, Tanaka K et al.. Incidental Lewy body disease in a patient with REM sleep behavior disorder. Neurology. 1995; 45 709-712
50 Wright B A, Rosen J R, Buysse D J, Reynolds C F, Zubenko G S. Shy-Drager syndrome presenting as a REM behavioral disorder. J Geriatr Psychiatry Neurol. 1990; 3 110-113
51 Plazzi G, Montagna P. Remitting REM sleep behavior disorder as the initial sign of multiple sclerosis. Sleep Med. 2002; 3 437-439

W. Elon FlemingM.D.

Medical Director, Sleep Disorders Center, Island Hospital

1211 24th Street, Anacortes, WA 98221